Beta Finch - S&P 100 - EN

More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Gilead Sciences' second quarter 2026 results — and Jordan, this is a big one.

JORDAN: It really is. Big numbers, big acquisitions, big pipeline news.

ALEX: Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good to have that out there. Okay, let's talk numbers. Gilead's base business — that's total product sales excluding the COVID drug Veklury — came in at $7.6 billion, up 10% year-over-year. That's their strongest second-quarter growth in three years.

ALEX: And it's broad-based too. HIV sales were up 12% to $5.7 billion, Trodelvy in oncology up 26%, and Livdelzi in liver disease more than doubled. On the back of that, management raised full-year HIV growth guidance to 9-10%, up from 8%.

JORDAN: The headline stat for me was PrEP — that's HIV prevention. Quarterly PrEP sales topped $1 billion for the first time, doubling year-over-year, putting that business on a $4 billion annual run rate. Yeztugo, their twice-yearly injectable, is now the leading option for new PrEP starts and even leads the switch market after just four quarters on the market.

ALEX: And they shared something pretty striking — more than 70% of Yeztugo patients are coming back for their second injection at six months, meaning they get a full year of protection. That persistency rate is apparently well above anything else in the category.

JORDAN: Now, EPS is where things get messy — but for a good reason. Non-GAAP diluted EPS was actually negative $6.75 for the quarter.

ALEX: Wait, negative? That sounds alarming.

JORDAN: It sounds alarming, but it's really an accounting story. Gilead closed three acquisitions this quarter — Arcellx, Tubulis, and Ouro Medicines — totaling about $11.2 billion in acquired R&D expense, which under accounting rules gets taken as a hit all at once. Strip that out, along with a one-time non-cash revenue item, and EPS was actually $2.27 for the quarter — up about 13% year-over-year on an apples-to-apples basis. That's outpacing revenue growth, which tells you there's real operating leverage in this business.

ALEX: Right, and full-year guidance reflects that same split — they're now guiding to $30.1 to $30.4 billion in total product sales, raised from prior guidance, but full-year EPS on a GAAP-ish basis is guided negative because of those acquisition costs. Excluding the deal noise, full-year EPS guidance is $8.50 to $8.85, actually raised slightly on the low end.

JORDAN: So the deals are the real story of the quarter, strategically speaking. Let's unpack them. Arcellx gives Gilead full ownership of anito-cel, their multiple myeloma cell therapy — that's five months from its PDUFA date, so a launch is coming. Tubulis brings an antibody-drug-conjugate platform, and there's already exciting early data on GS-8824 in ovarian cancer — 61% response rate in a tough, pretreated population.

ALEX: And on the existing portfolio side, it wasn't just an acquisitions quarter. Trodelvy got approved for first-line metastatic triple-negative breast cancer, roughly doubling its addressable patient population. Livdelzi, the liver disease drug, posted positive phase III data that could expand its use. And they launched Hepcludex, the first-ever approved treatment for chronic hepatitis D.

JORDAN: One thing that jumped out in the Q&A — an analyst pushed CEO Dan O'Day on whether Gilead still cares about diversifying away from HIV, since HIV remains such a dominant chunk of revenue. His answer was basically "yes, but we're doing it two ways" — diversifying within HIV itself with new dosing options, dai

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
**Beta Finch Podcast Script - Gilead Q1 2026 Earnings**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Gilead Sciences' first quarter 2026 results - and wow, what a quarter this was for the biotech giant.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

Jordan, Gilead came out swinging with some pretty impressive numbers, didn't they?

**JORDAN:** Absolutely, Alex! Let's start with the headline numbers because they're quite strong. Total product sales hit $6.9 billion, up 5% year-over-year. But here's the kicker - if you exclude their COVID drug Veklury, their base business grew 8% to $6.8 billion. That's solid growth for a company Gilead's size.

**ALEX:** And they're not just talking the talk - they're raising guidance across the board. What stood out to you most about their updated outlook?

**JORDAN:** The HIV business is absolutely on fire. They raised their HIV growth expectations from 6% to 8% for the full year, and get this - their PrEP drug Yes2Go, which prevents HIV, is now expected to hit $1 billion in sales. That would make it a blockbuster drug in just its first full year on the market!

**ALEX:** That's remarkable. Let's break down what's driving this HIV success, because it seems like Gilead is firing on all cylinders here.

**JORDAN:** It really is a multi-pronged success story. Their flagship HIV treatment Biktarvy continues to dominate with over 52% market share in the U.S. - that's a drug pulling in $3.4 billion in the quarter alone. But the real star is Yes2Go, their twice-yearly injectable HIV prevention drug. Sales jumped 72% just from the previous quarter to $166 million.

**ALEX:** And during the Q&A, management seemed pretty confident about Yes2Go's trajectory. What are they seeing that makes them so optimistic?

**JORDAN:** Great question! Johanna Mercier, their commercial chief, mentioned some really encouraging metrics. They now have 95% insurance coverage with 95% of those having zero copay for patients. They're seeing strong uptake from both people switching from other drugs and completely new users. And perhaps most importantly, the "persistency" - meaning people coming back for their second injection - is looking really good.

**ALEX:** Now, Gilead wasn't just focused on HIV this quarter. They made some major acquisition moves. Can you walk us through what they're buying and why?

**JORDAN:** This is where it gets really interesting from a strategic perspective. They closed three major deals: Arcellx for their cancer cell therapy anitocel, they're buying Tubulis for their antibody-drug conjugate technology, and Oral Medicines for autoimmune treatments. The total upfront cost? About $11.5 billion.

**ALEX:** That's a lot of cash! How are investors supposed to think about these deals?

**JORDAN:** Well, it's definitely impacting their near-term earnings - they're actually projecting a loss per share for 2026 because of these upfront costs. But management seemed confident these are strategic investments for the long term. The Arcellx deal brings them anitocel, which they believe could be best-in-class for multiple myeloma. And Tubulis gives them next-generation cancer drug technology that goes beyond their current Trodelvy franchise.

**ALEX:** Speaking of Trodelvy, how's their existing oncology business performing?

**JORDAN:** Trodelvy is growing nicely - up 37% year-over-year to $402 million. They're expecting regulatory decisions this year that could expand its use to first-line breast cancer treatment, which would be a significant ma

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
# Beta Finch Podcast Script: Gilead Q4 2025 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and as always, I'm joined by my co-host Jordan. Today we're unpacking Gilead Sciences' Q4 2025 results - and folks, there's a lot to dig into here.

Before we jump in though, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And what a quarter this was for Gilead! The biotech giant just wrapped up what CEO Dan O'Day called "a remarkable year" - and the numbers certainly back that up. They hit $28.9 billion in total product sales for 2025, beating their guidance range and showing some serious momentum heading into 2026.

**ALEX:** Absolutely, Jordan. Let's break down those headline numbers first. Total product sales came in at $7.9 billion for Q4, up 5% year-over-year. But here's what caught my attention - when you strip out their COVID drug Veclury, which has been declining as expected, their base business actually grew 7% in the quarter and 4% for the full year.

**JORDAN:** That's a key distinction, Alex. And speaking of key numbers, their HIV business - which is still their cash cow - delivered $20.8 billion in sales for the year, up 6%. But here's where it gets interesting: they faced an estimated $900 million headwind from Medicare Part D redesign changes. Without that policy impact, their HIV business would have grown 10%.

**ALEX:** That Medicare Part D impact is huge context, Jordan. For listeners who might not be familiar, this was a policy change that affected how drug pricing works for seniors on Medicare. So when Gilead says their underlying HIV business grew 10%, that's actually pretty impressive growth for what's considered a mature market.

**JORDAN:** Exactly. And let's talk about the star of the show - YES2GO. This is their twice-yearly injectable HIV prevention drug that launched in 2025, and it's already showing blockbuster potential. They did $150 million in sales for the year, and here's the kicker - they're guiding for $800 million in 2026.

**ALEX:** That's more than a 5x increase, Jordan. During the Q&A, analysts were really pressing on how realistic that number is. Management seems confident though, citing 90% payer coverage already - including all major insurers - with about 90% of covered patients getting it with zero co-pay.

**JORDAN:** The coverage piece is critical, Alex. Commercial launch is one thing, but getting insurance companies to pay for a premium-priced injectable is another. The fact that they hit their 90% coverage target well ahead of their one-year timeline suggests the value proposition is resonating with payers.

**ALEX:** Let's shift to their pipeline, because this is where things get really interesting for long-term investors. They have four potential product launches coming in 2026, plus five Phase III data readouts across HIV, cancer, and liver disease.

**JORDAN:** Right, and this diversification strategy is really starting to pay off. Their cancer drug Trodelvy grew 6% to $1.4 billion, and they just got positive Phase III data that could expand it from second-line to first-line treatment in triple-negative breast cancer. That's potentially doubling the addressable market.

**ALEX:** And Trodelvy isn't their only oncology play. They're preparing to launch something called Anidocel - a CAR-T therapy for multiple myeloma. The clinical data looks strong with a 96% overall response rate and what they're calling a "best-in-disease" safety profile.

**JORDAN:** The safety piece is huge in CAR-T, Alex. These are powerful but potentially toxic

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: INDUSTRIALS (https://betafinch.com/groups/INDUSTRIALS)
──────────
Welcome to Beta Finch, your AI-powered earnings breakdown of the companies moving the market. I'm about to walk through GE Aerospace's Q2 2026 results.

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, here with Jordan, and today we're digging into GE Aerospace's second quarter 2026 numbers. Before we get into it — quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: And GE Aerospace gave us a lot to talk about this quarter, Alex. This wasn't just a beat — they raised guidance across the board.

ALEX: Right, let's start with the headline numbers. Orders up 17%, revenue up 24% — that's the fifth straight quarter of at least 20% revenue growth — operating profit up 18%, EPS up 22% to $2.02, and free cash flow jumped 43% to $3 billion.

JORDAN: That free cash flow number really stood out to me. They actually reduced working capital even while earnings grew 24%. CFO Rahul Ghai called that out specifically — better receivables, better inventory management. That's not easy to pull off when you're scaling this fast.

ALEX: And both segments contributed. Commercial Engines and Services, or CES, was up 27% in revenue, and Defense and Propulsion, DPT, grew 16%. CES margins did dip about 130 basis points to 21.7%, but that's from investing in installed engine growth — basically the cost of feeding future services revenue.

JORDAN: Which is the classic GE Aerospace story right now — sell more engines at lower margin today, because those engines come back for decades of high-margin maintenance work. Their backlog is over $210 billion total, with $170 billion of that in commercial services alone.

ALEX: So given all that strength, they raised full-year guidance pretty significantly. Revenue now expected to grow high teens, up from low double digits. EPS guidance moved to $7.65 to $7.85, and free cash flow guidance jumped to $8.9 to $9.2 billion.

JORDAN: What's interesting is CEO Larry Culp explained why they didn't raise guidance last quarter despite a strong Q1 — there was real geopolitical and demand uncertainty back in April. He said flat out, "we would play April all over again in the same way." They wanted to see how customer behavior actually played out before getting ahead of themselves.

ALEX: And it turns out demand held up remarkably well. Culp mentioned parked CFM56 aircraft have actually declined since March, and departures — which were roughly flat in the first half — are expected to gradually pick back up in the second half.

JORDAN: The demand side really isn't the constraint here anymore. Multiple times on the call, both Culp and Ghai said this is now a supply-side story, not a demand-side one. Spare parts delinquencies — meaning shipments delayed due to material availability — were actually up 20% sequentially, even as they're growing spare parts revenue over 25%.

ALEX: That's a good problem to have, but still a real constraint. They talked about using their "Flight Deck" operational system to chip away at it — things like a Kaizen event with supplier GKN that led to a 90% improvement in inspection time, and AI-driven demand signal processing that cut processing time by nearly 90% across 190 parts.

JORDAN: And on the product side, a big milestone — they certified the LEAP-1B durability kit, which should roughly double time on wing. That's huge for airlines worried about engine cost of ownership, which came up multiple times in the Q&A. Analysts pushed hard on whether airlines can keep absorbing these costs.

ALEX: Culp's answer was essentially: we hear you, we're not taking a victory lap, but we're doing everything we can short-term — like getting LEAP

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: INDUSTRIALS (https://betafinch.com/groups/INDUSTRIALS)
──────────
# Beta Finch Podcast Script: GE Aerospace Q1 2026 Earnings

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the numbers that matter. I'm Alex, and I'm here with my co-host Jordan to unpack GE Aerospace's first quarter 2026 results.

**JORDAN**: Hey everyone! And before we jump in, Alex, we need to make sure our listeners know that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX**: Absolutely, Jordan. Now, let's talk about GE Aerospace - and wow, what a quarter this was! The aerospace giant just delivered some seriously impressive numbers despite operating in what CEO Larry Culp called "a dynamic geopolitical environment."

**JORDAN**: Right off the bat, Alex, these top-line numbers are eye-popping. Orders up 87% - that's not a typo, folks - with their Commercial Engines & Services segment nearly doubling. Revenue jumped 29%, operating profit grew 18%, and earnings per share increased 25% to $1.86.

**ALEX**: And let's not forget free cash flow up 14% to $1.7 billion. But Jordan, what really caught my attention was how they're navigating the Middle East conflict. They're being pretty transparent about the headwinds - reducing their full-year air traffic departures outlook from mid-single-digit growth to flat to low single-digit growth.

**JORDAN**: That's a great point, Alex. It shows mature management recognizing reality while still delivering strong results. What's fascinating is their services backlog - over $170 billion, up nearly $30 billion since 2024. That's incredible visibility for a cyclical business.

**ALEX**: Speaking of services, their spare parts business is absolutely on fire. Demand is so strong that they're actually seeing delinquencies - meaning they can't ship parts fast enough to meet demand. Spare parts orders are up over 30% year-over-year, and they're entering Q2 with more than 95% of spare parts revenue already in backlog.

**JORDAN**: It's almost a good problem to have, right? Though I'm sure their customers don't love waiting for parts. What really stood out to me was their "Flight Deck" initiative - this is their digital transformation program that's apparently changing how they operate. They gave some concrete examples, like helping a supplier increase output by over 40% and reducing LEAP engine repair times by over 50%.

**ALEX**: That's the kind of operational excellence that creates lasting competitive advantages. And speaking of competitive advantages, let's talk about their market position. They've got 80,000 engines in their fleet with more than 2.3 billion flight hours of experience.

**JORDAN**: Plus they're investing heavily in the future - $1 billion in U.S. manufacturing for the second consecutive year, plus $100 million in supplier equipment and tooling. They're not just managing the present; they're building for the next decade.

**ALEX**: Now, let's dig into the segments. Commercial Engines & Services saw orders grow 93%, with services up 49% and equipment more than tripling. Their LEAP engine program continues to be a star performer with deliveries up 63%.

**JORDAN**: And on the defense side - Defense & Propulsion Technologies had orders up 67%, including a massive $1.4 billion contract for T408 engines for the Marine Corps. This is their second consecutive quarter with defense book-to-bill above 2, which means they're winning more new business than they're delivering.

**ALEX**: The Q&A session revealed some interesting insights too. When asked about potential prebuying by customers ahead of disruptions, CEO Culp was pretty clear - they're not seeing that behavior. The strength is genuine demand, not artificial pul

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: INDUSTRIALS (https://betafinch.com/groups/INDUSTRIALS)
──────────
**BETA FINCH PODCAST SCRIPT**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn corporate earnings calls into conversations that actually make sense. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're diving into GE Aerospace's Q4 2025 earnings call, and wow - this was one impressive quarter to close out the year.

**ALEX:** Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Absolutely. Now Alex, let's talk about these numbers because GE Aerospace just delivered what CEO Larry Culp called "an outstanding year." We're looking at some seriously impressive double-digit growth across the board.

**ALEX:** The headline numbers are pretty striking, Jordan. For Q4, orders were up 74% - that's massive. Revenue increased 20%, earnings per share jumped 19% to $1.57, and free cash flow grew 15%. But the full-year picture is even more compelling.

**JORDAN:** Right, and that's where it gets really interesting. Full-year orders up 32%, revenue up 21%, and here's the kicker - operating profit grew by $1.8 billion dollars. That's not a percentage, that's $1.8 billion in absolute dollars. Free cash flow was up $1.5 billion to $7.7 billion total.

**ALEX:** What I found fascinating was how CEO Larry Culp framed this. He kept coming back to their purpose statement: "We invent the future of flight, lift people up, and bring them home safely." But then he backed that up with some hard data - nearly one million people are in flight right now with GE technology under wing.

**JORDAN:** And let's talk about that backlog, Alex. They're sitting on roughly $190 billion in backlog, up nearly $20 billion over the last year. That's not just a number - that's visibility into future revenue streams. When you have that kind of contracted future business, it gives you incredible confidence in your guidance.

**ALEX:** Speaking of guidance, let's break down what they're expecting for 2026. They're forecasting low double-digit revenue growth, with commercial services up mid-teens. Operating profit is expected to hit $9.85 to $10.25 billion - that's up a billion dollars at the midpoint.

**JORDAN:** And here's what caught my attention - CFO Rahul Ghai said they expect to hit that $10 billion operating profit milestone in 2026, which is two years earlier than their original outlook. That's not just meeting expectations, that's accelerating past them.

**ALEX:** The EPS guidance of $7.10 to $7.40 represents nearly 15% growth at the midpoint. And free cash flow? They're projecting $8 to $8.4 billion. Jordan, when you look at these numbers, what's really driving this performance?

**JORDAN:** It's really a tale of two segments, Alex. Their Commercial Engines & Services segment is absolutely on fire. CES orders were up 35% for the year, revenue grew 24%, and here's the key - services orders up 27% and revenue up 26%. That's the high-margin aftermarket business that keeps printing money for decades after an engine is sold.

**ALEX:** Right, and their Defense, Power & Technology segment, while smaller, also showed solid growth with orders up 19% and revenue up 11%. But let's dig into what's happening operationally because there were some really interesting strategic moves announced.

**JORDAN:** Absolutely. They're doing a major organizational restructuring. They're expanding their CES division to include their Technology & Operations team, now led by Muhammad Ali. The goal is better end-to-end engine lifecycle management. And they're elevating their customer-facing teams to report directly to the CEO.

**ALEX:** That organizational change seems designed t

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the numbers and the noise from corporate earnings calls and turn them into something you can actually digest. I'm Alex.

JORDAN: And I'm Jordan. Before we dive in, quick disclaimer:

ALEX: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: With that out of the way — Alex, today we're on GE Vernova, ticker GEV, Q2 2026. And this is one of those quarters where I read the numbers twice because they seemed almost too good.

ALEX: Right, let's just start with the headline: orders came in at $24.2 billion for the quarter, up 88% year-over-year. That's a book-to-bill ratio of over 2x, meaning they're booking twice as much business as they're actually shipping and billing right now.

JORDAN: Which tells you the backlog is just ballooning. And it did — total backlog hit $176 billion, up $13 billion sequentially. CEO Scott Strazik said they're on track for $200 billion by 2027.

ALEX: The engine behind all this is really Gas Power. They signed 20 gigawatts of new orders and slot reservations this quarter alone, pushing their total gigawatts under contract from 100 to 116. And they're now saying they expect to hit at least 125 gigawatts by year-end.

JORDAN: What stood out to me is the mix — more than half of that contracted capacity is for their big HA turbines, the ones expected to run baseload for decades. That's not speculative demand, that's utilities and data centers locking in power for the long haul. And notably, about 80% of that demand is still traditional customers, only 20% data centers — so despite all the AI hype, this isn't just a data center story.

ALEX: Though the data center piece is growing fast too. Electrification booked $2.7 billion in data center orders this quarter, bringing the first-half total north of $5 billion — more than double all of 2025.

JORDAN: Let's talk margins, because that's really the story underneath the story. Adjusted EBITDA grew 61% year-over-year to $1.2 billion, and margin expanded 340 basis points. First-half margins are up 360 basis points versus last year, even as lower-margin-mix equipment revenue grows faster than services.

ALEX: And free cash flow — this is the number that jumped out at me — $5.1 billion generated in the quarter alone. Year to date they're at roughly $10 billion, which is already two and a half times what they did in all of 2025.

JORDAN: A lot of that is working capital benefit from customer down payments on all those gas turbine slot reservations. It's real cash, but investors should understand some of that first-half strength is front-loaded — CFO Ken Parks was upfront that second-half free cash flow will be notably lower than the first half.

ALEX: Which is why the full-year guidance raise is still notable in context. Revenue guidance moved up to $45.5 to $46.5 billion, and free cash flow guidance jumped from $6.5-$7.5 billion to $11.5-$12.5 billion.

JORDAN: That's almost double the original free cash flow guide. EBITDA margin guidance held steady at 12-14% for the year.

ALEX: Let's hit segment performance quickly. Power segment orders more than doubled, revenue up 14%, EBITDA margin expanded 320 basis points to 18.8%. Electrification was even more dramatic — orders up 66% to $6.3 billion, revenue up 68% on a reported basis, margin up 700 basis points to 18.4%.

JORDAN: Wind is the laggard, as expected. Orders down 40%, mostly onshore weakness in North America tied to permitting delays and tariff uncertainty. EBITDA losses of $275 million this quarter, and they're still guiding to roughly $400 million in losses for the full year. Management's basically saying: we're managing what we can control there and waiting for pol

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
**BETA FINCH PODCAST SCRIPT**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into quarterly results to help you understand what's really driving the markets. I'm Alex, and joining me as always is Jordan.

**JORDAN:** Hey everyone! Today we're breaking down GE Vernova's absolutely explosive Q1 2026 results. And Alex, before we jump in, I know we need to mention—

**ALEX:** Absolutely. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. Now Jordan, let's talk about these numbers because wow—GE Vernova just delivered what might be one of the most impressive quarters we've seen in the industrial space.

**JORDAN:** Alex, where do I even start? Orders up 71% year-over-year to $18.3 billion, with a book-to-bill ratio of 2.0. That means for every dollar of revenue they recognized, they booked two dollars in new orders. Their backlog is now sitting at $163 billion—that's billion with a 'B'—and they're saying they'll hit $200 billion in backlog by 2027, a full year ahead of schedule.

**ALEX:** The cash generation story here is just phenomenal. They generated $4.8 billion in free cash flow in just one quarter—that's more than their entire 2025 full-year free cash flow of $3.7 billion. What's driving this massive cash generation?

**JORDAN:** It's really the working capital dynamics. When you're booking orders this aggressively, especially in long-cycle businesses like power generation, you're getting significant down payments upfront. They had $5.3 billion in working capital benefits, primarily from higher down payments on those Power and Electrification orders. It's like getting paid before you do most of the work—a beautiful business model when demand is this strong.

**ALEX:** Let's break down the segments because each one tells a different story. Starting with Power—their bread and butter—revenue up 10%, but EBITDA margins expanded a massive 500 basis points to 16.3%.

**JORDAN:** The Power segment is firing on all cylinders. They shipped 25 gas turbines in the quarter, up 32% year-over-year, and their pricing is getting significantly better. CEO Scott Strazik said their 2026 orders are priced 10-20% higher than Q4 2025 levels on a dollar-per-kilowatt basis. When you have three-year lead times and customers desperate for power generation capacity, you can command premium pricing.

**ALEX:** And this isn't just traditional utility demand. About 20% of their 100 gigawatts under contract are directly supporting data centers. The AI boom is creating this massive secondary demand for power infrastructure that I don't think many investors fully appreciate yet.

**JORDAN:** Exactly! And speaking of underappreciated, let's talk Electrification—this segment is becoming a monster. Orders up 86% year-over-year, and here's the kicker: their Q1 data center orders alone were $2.4 billion, which is more than their entire full-year 2025 data center business.

**ALEX:** The Prolec acquisition is paying off big time. They bought the remaining 50% stake for $5.3 billion in February, and Prolec's backlog has grown 25% just since they announced the deal at Q3 earnings. That's incredible customer enthusiasm for the combined entity.

**JORDAN:** What I love about the Electrification story is the portfolio breadth. They're not just selling transformers—they've got HVDC systems, substations, grid automation software. CFO Ken Parks mentioned they closed their first Energy Management System order, which combines power conversion, substation equipment, and grid software into an integrated solution for data centers.

**ALEX:** The company is really positioning itself as the one-stop shop for electrification. Strazik gave this great example of a project where

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
# Beta Finch Podcast Script - GE Vernova Q4 2025 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the latest corporate results so you don't have to. I'm Alex, and joining me as always is Jordan. Today we're diving into GE Vernova's fourth quarter 2025 earnings - and wow, what a quarter this was.

**JORDAN:** Absolutely, Alex. But before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX:** Thanks Jordan. So GE Vernova - this is the power generation and electrical equipment spinoff from GE that's been really making waves since going public. Jordan, what jumped out at you first from these numbers?

**JORDAN:** The scale is just incredible, Alex. We're talking about a $150 billion backlog - that's up 25% or $31 billion year-over-year. And they booked $59 billion in orders for the full year, up 34%. For context, their revenue was $38 billion, so they're booking orders at about 1.5 times their current revenue run rate.

**ALEX:** That's a massive order book. And CEO Scott Strazik seemed particularly excited about their gas power business. Can you break down what's happening there?

**JORDAN:** Gas power is absolutely on fire - no pun intended. They went from having 46 gigawatts under contract at the start of 2025 to 83 gigawatts by year-end. That's almost doubling their contracted capacity in a single year. And here's the kicker - they expect to hit 100 gigawatts by the end of 2026.

**ALEX:** What's driving this demand surge?

**JORDAN:** It's really the perfect storm of factors. You've got data centers consuming massive amounts of power, aging grid infrastructure, and the need for reliable baseload power as renewable intermittency creates challenges. Strazik mentioned they signed 6 gigawatts of new gas contracts just in the last three weeks of December alone.

**ALEX:** And they're not just winning on volume - they're getting better pricing too, right?

**JORDAN:** Exactly. This was one of the most interesting parts of the call. They added $8 billion in equipment backlog margin dollars in 2025 - that's more than the previous two years combined. In their Power segment specifically, they saw 11 percentage points of margin improvement in their equipment backlog. Strazik mentioned their current slot reservation agreements are pricing 10 to 20 points higher than their existing backlog.

**ALEX:** That pricing power is impressive. Now, it wasn't all good news though. Their Wind segment continues to struggle, particularly with offshore projects.

**JORDAN:** Yeah, the Wind segment is definitely the problem child. They had $600 million in losses for the year, which was worse than their $400 million expectation. The big issue was a U.S. government stop-work order on December 22nd that halted all offshore wind construction, including their Vineyard Wind project that was nearly complete.

**ALEX:** That's got to be frustrating - being so close to finishing a project and then getting shut down by regulatory action.

**JORDAN:** Absolutely. CFO Ken Parks said they only had 10 turbines left needing blades and 1 turbine left to install when the order came down. The good news is they got an injunction yesterday, so they might be able to resume work. But if they can't complete those remaining 11 turbines, it could impact 2026 revenue by about $250 million.

**ALEX:** Let's talk about their Electrification business - that seems to be a real growth driver.

**JORDAN:** This is probably the most exciting part of the story long-term. Electrification revenue grew 26% in 2025, and they're expecting it to hit $13.5 to $14 billion in 2026. To put that in perspective, this business was doing about $5 billion in r

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: ENERGY (https://betafinch.com/groups/ENERGY)
──────────
**WELCOME BACK TO BETA FINCH**

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, bringing you the numbers and the narrative behind the companies moving markets. I'm Alex.

JORDAN: And I'm Jordan. Today we're diving into EOG Resources' second quarter 2026 results — and Alex, this one's got some genuinely fun stuff in it, including oil wells in the UAE.

ALEX: We'll get there. But first, the disclaimer, because we always start with it: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good, glad that's out of the way. Okay Alex, break down the numbers for us — this was apparently a record quarter for EOG.

ALEX: It really was. Adjusted earnings per share came in at $5.70, adjusted cash flow per share hit $8.29, and free cash flow was $2.8 billion — all record levels. CEO Ezra Yacob credited robust oil prices, but he was careful to frame this as more than just a commodity tailwind — he called it "consistent, high-quality execution."

JORDAN: And the shareholder return story backs that up. They returned just over $1.8 billion to shareholders in the quarter — $540 million in dividends, $1.3 billion in buybacks. They've now got $11.7 billion left on the repurchase authorization, and they're reiterating that commitment to return at least 70% of annual free cash flow in 2026.

ALEX: The balance sheet numbers are what really stood out to me. $4.9 billion in cash, net debt of just $3 billion, and — this is the eye-popping one — a WTI breakeven price below $50 a barrel for the whole 2026 program. That's a lot of cushion.

JORDAN: Twenty-eight years without a dividend cut or suspension, too. That's not a typo — that track record spans multiple oil crashes, COVID, you name it.

ALEX: Right, and guidance-wise, they're holding capex steady at $6.5 billion for the year, targeting 5% oil production growth and 14% total production growth. Let's talk strategy now, because the headline story this quarter was really about exploration — specifically, international exploration.

JORDAN: Yeah, this was the most interesting part of the call for me. EOG drilled two one-mile wells in the UAE with ADNOC, and in the first 30 days those wells averaged over 25,000 barrels of oil per well — flowing naturally, not even on artificial lift yet.

ALEX: And Keith Trasko, their SVP of Exploration, said the geologic analog they're using is the Eagle Ford — similar rock type, similar product mix, similar GOR and API gravity. So this isn't some totally unknown formation to them; it rhymes with a play they've drilled for over a decade.

JORDAN: Executives were pretty clear-eyed about it too — Ezra called it early innings, a 900,000-acre concession, three-year exploration phase, and ADNOC has an option to back in down the line. They're not rushing toward a final investment decision.

ALEX: There was also a really human moment in the Q&A about the Iran conflict's impact on operations. Ezra said that despite intermittent operations in Bahrain due to the conflict, the crisis actually became — his words — "an opportunity to stress-test the relationship with our partners," and that communication with ADNOC and Bapco had been transparent throughout.

JORDAN: Domestically, the other big reveal was a new Austin Chalk "sweet spot" in Lavaca County, Texas — 60,000 net acres leased at around $1,200 an acre, adjacent to their Eagle Ford position. Twelve wells drilled so far showing sub-one-year payouts and returns over 100% at $65 WTI.

ALEX: Jeff Leitzell, the COO, framed that as roughly a full extra year of drilling inventory for their San Antonio division. And it's a good example of their broader theme this quarter — using their in-house techni

This episode includes AI-generated content.